A versatile live attenuated oral *Salmonella* DNA vaccination platform for modulating T cell immunity against tumor neoantigens

VAXIMM AG, Basel, Switzerland, and VAXIMM GmbH, Mannheim, Germany.

### High safety and good tolerability

- Readily combinable with other immune therapies
- Approved carrier bacterium, with excellent longstanding safety record
- Low therapeutic doses much below Vivitif® (typically $10^7$ – $10^8$ CFU)
- No anti-vector immunity and little to no vector-related side effects
- Suitable for multi target and neoantigen approaches

### Fast, robust and flexible manufacturing

- Attractive cost of goods
  - Plug and play system
  - Established methods (GMP manufacturing, QA/QC, etc.)
  - Stable formulation for 3 years independently of the insert
  - No galenic formulation incompatibilities
  - Neoantigen/ personalized vaccine approaches: 15-day turnaround time
  - Large number of epitopes possible

### Natural, efficient and easy way to activate T-cells

- Strong antigen expression allowing specific T-cells to target the tumor
- Oral delivery targeting the lymphatic tissue of the gut
- Boosting possible without anti-carrier immunity
- Self-adjuvant through concomitant bacterial Ty21a infection
- Very low amount of genetic material administered corresponding to 1 ng of DNA in $10^7$ CFU, far below 500-1000 µg of RNA used in recent studies

### Immunogenicity of different polypeptide constructs

- Substantial systemic T-cell response detected
  - Different constructs encoding multiple CD8 and CD4 T cell epitopes in a “string-of-beads”
  - Dose, treatment schedule, ordering and linkage strategy greatly influences the immunogenicity

### Best-in-class technology for neoantigen vaccination

- Novel approach for targeting neoepitopes
  - Short time to oral administration
  - Objective: neoantigen identification + 15 days
  - Accelerated path to phase 1 POC data
  - Unique administration mode
  - Strong rationale to combine with checkpoint inhibitors

### Delivery Technology

- **VAXIMM**
  - Neoantigen discovery + 15 days

- **Company A**
  - 115 days

- **Company B**
  - 90 days

- **Company C**
  - 75 days

*according to published data

---

Heinz Lubena, PhD (Chief Operating Officer)
VAXIMM GmbH, Harrlachweg 2, 68163 Mannheim, Germany
**+49 621 8359 687 10**, [heinz.lubena@vaximm.com](mailto:heinz.lubena@vaximm.com) www.vaximm.com